Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RCZY690 in advanced malignant solid tumors
NCT07806175Phase 2Not yet recruiting
- Sponsor
- Yantai Rongchang Pharmaceutical
- Start
- Sep 2026
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
A Phase 2 trial of RCZY690 in malignant solid tumor, sponsored by Yantai Rongchang Pharmaceutical. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
RCZY690
03
Conditions
malignant solid tumor
Beyond the preview
Go deeper on NCT07806175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07806175.